Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mammary Cancer Clear all
Terminated Phase 2 Interventional Results available

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

NCT03733119
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Akt/ERK Inhibitor ONC201, Methionine-Restricted Diet
Drug · Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 24, 2026, 4:02 PM EDT
Enrolling by invitation Not applicable Interventional

Symptom Monitoring Using Patient-Report to Improve Medication Use

NCT06765707
View directory record Official record
Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Endocrine Therapy
Interventions
Pharmacist delivered symptom monitoring and management
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

NCT00004067
View directory record Official record
Conditions
Breast Cancer
Interventions
herceptin, adriamycin, cyclophosphamide, taxol
Biological · Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
2,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2019
U.S. locations
141
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings

NCT03697200
View directory record Official record
Conditions
Aromatase Inhibitor, Musculoskeletal Symptoms, Postmenopausal Breast Cancer Survivors
Interventions
APA, Sham APA control, Education control
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Tremelimumab in Patients With Advanced Solid Tumors

NCT02527434
View directory record Official record
Conditions
Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
San Francisco, California • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

NCT00003199
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen citrate, busulfan, thiotepa, melphalan, aldesleukin, sargramostim, peripheral blood stem cell transplantation, radiation therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 24, 2026, 4:02 PM EDT
Active, not recruiting Not applicable Interventional

Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors

NCT06260332
View directory record Official record
Conditions
Breast Cancer
Interventions
Supportive Care (Fitbit)
Behavioral
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

NCT02167854
View directory record Official record
Conditions
Breast Cancer
Interventions
BYL719, LJM716, TRASTUZUMAB
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients

NCT01042938
View directory record Official record
Conditions
Breast Cancer
Interventions
Curcumin C3 Complex, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

NCT02187783
View directory record Official record
Conditions
Tumors With CDK4/6 Pathway Activation
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
61
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Not applicable Interventional Results available

Symptom Management for YA Cancer Survivors

NCT04035447
View directory record Official record
Conditions
Cancer, Young Adult, Pain, Psychological Distress, Fatigue, Breast Cancer, Melanoma, Hematologic Cancer, Germ Cell Tumor, Endocrine Cancer
Interventions
Behavioral Symptom Management for Young Adult Cancer Survivors
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 24, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

NCT05660083
View directory record Official record
Conditions
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer
Interventions
L-NMMA
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 24, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors

NCT07001241
View directory record Official record
Conditions
Cancer-related Fatigue, Breast Cancer, Prostate Cancer
Interventions
Telehealth Exercise Program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Aurora, Colorado • Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 24, 2026, 4:02 PM EDT
Recruiting Not applicable Interventional

Cardiometabolic Screening Program

NCT05386719
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer
Interventions
Prescreening, Screening and Enrollment, Baseline, Interpret BMI, Interpret HbA1c, Interpret lipid panel and assess other risk factors, Assess 10 year risk of cardiovascular event, Recommendations, Follow-Up
Other · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional

Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer

NCT00002662
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, paclitaxel
Drug
Lead sponsor
Aventis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
32
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Heart Health After Cancer Treatment (HEART-ACT)

NCT06055803
View directory record Official record
Conditions
Breast Cancer
Interventions
Intake Session, Individual Sessions, Group Sessions, Graduation, Exercise
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 24, 2026, 4:02 PM EDT
Recruiting Phase 1 Interventional

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

NCT06218303
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor, Selective estrogen receptor modulator (SERM)
Biological · Drug
Lead sponsor
Finn, Olivera, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Not applicable Interventional

CHESS Caregivers Study: Web-based Support for Informal Caregivers in Cancer

NCT00214162
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Comprehensive Health Enhancement Support System, computer with internet
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

NCT01009788
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation, brca2 Gene Mutation
Interventions
ABT-888, temozolomide
Drug
Lead sponsor
Steven J Isakoff, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

NCT00146562
View directory record Official record
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
Interventions
Darbepoetin Alfa, Pegfilgrastim, Paclitaxel, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
6
States / cities
Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 24, 2026, 4:02 PM EDT
Terminated Phase 1 Interventional

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

NCT01407562
View directory record Official record
Conditions
Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female
Interventions
Pazopanib, Paclitaxel, Carboplatin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 24, 2026, 4:02 PM EDT
Active, not recruiting No phase listed Observational

A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

NCT05889988
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Aitkin, Minnesota • Baxter, Minnesota • Brainerd, Minnesota + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 24, 2026, 4:02 PM EDT
Terminated Not applicable Interventional

Preventing Lymphedema in Axillary Lymph Node Dissection

NCT03428581
View directory record Official record
Conditions
Lymphedema, Breast Cancer, Melanoma
Interventions
ALND with ARM +/- LVB, ALND
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 24, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

NCT01975831
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 24, 2026, 4:02 PM EDT